Jamie Oliver
Chief Medical Officer Starton Therapeutics
Seminars
Tuesday 15th September 2026
Reengineering Lenalidomide Exposure in Multiple Myeloma Bispecific Therapy: Controlled Delivery of STAR-LLD
2:30 pm
- Adding IMiDs (e.g., lenalidomide) to bispecifics deepens response in RRMM, but severe (Grade 3/4) neutropenia, thrombocytopenia, and infections lead to discontinuations or dose reductions
- STAR-LLD’s continuous SC delivery avoids toxicity by maintaining lenalidomide above the efficacy threshold (26 ng/mL) for target degradation without reaching peak levels that cause bone marrow suppression as seen with oral lenalidomide
- Phase 1b data (AACR 2025) for STAR-LLD showed a 100% ORR with zero Grade 3/4 drug-related hematologic toxicity or infections; a Phase 1 trial with elranatamab is underway to confirm enhanced responses without added toxicity
Tuesday 15th September 2026
Group Roundtable Discussions
3:00 pm
- Roundtable discussions are designed to be interactive, discursive deep dives where delegates break into smaller groups to explore a focused topic through candid, peer-led conversation. Each group will exchange experiences, challenges, and practical insights before reconvening to share key takeaways with the wider audience and with the conversation being facilitated by our seminar day leaders.
